These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32528750)

  • 21. Primary healthcare utilisation and self-rated health among patients with Irritable Bowel Syndrome: What are the impacts of comorbidities, gastrointestinal symptom burden, sense of coherence and stress?
    Norlin AK; Faresjö Å; Falk M; Jones MP; Walter S
    J Psychosom Res; 2019 Apr; 119():1-7. PubMed ID: 30947811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease.
    Adejumo AC; Ajayi TO; Adegbala OM; Adejumo KL; Alliu S; Akinjero AM; Onyeakusi NE; Ojelabi O; Bukong TN
    Liver Int; 2018 Aug; 38(8):1475-1486. PubMed ID: 29341392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs of irritable bowel syndrome in the UK and US.
    Maxion-Bergemann S; Thielecke F; Abel F; Bergemann R
    Pharmacoeconomics; 2006; 24(1):21-37. PubMed ID: 16445300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea.
    Talley NJ; Dennis EH; Schettler-Duncan VA; Lacy BE; Olden KW; Crowell MD
    Am J Gastroenterol; 2003 Nov; 98(11):2454-9. PubMed ID: 14638348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.
    Halmos EP; Power VA; Shepherd SJ; Gibson PR; Muir JG
    Gastroenterology; 2014 Jan; 146(1):67-75.e5. PubMed ID: 24076059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
    Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
    BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
    Harris LA; Baffy N
    Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome.
    Storr MA; Yüce B; Andrews CN; Sharkey KA
    Neurogastroenterol Motil; 2008 Aug; 20(8):857-68. PubMed ID: 18710476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
    Lacy BE; Patel H; Guérin A; Dea K; Scopel JL; Alaghband R; Wu EQ; Mody R
    PLoS One; 2016; 11(4):e0154258. PubMed ID: 27116612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.
    Paré P; Gray J; Lam S; Balshaw R; Khorasheh S; Barbeau M; Kelly S; McBurney CR
    Clin Ther; 2006 Oct; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic burden of irritable bowel syndrome in China.
    Zhang F; Xiang W; Li CY; Li SC
    World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Green Smoke, Red Flag: Cannabis and the Risk of Orbitopathy and Dermopathy in Thyrotoxicosis.
    Okpujie V; Ozumba S; Olaomi OA; Uwumiro FE; Ajiboye AE; Abesin O; Solomon RO; Ogunfuwa OM; Hassan JH; Opeyemi MR
    Cureus; 2023 May; 15(5):e39092. PubMed ID: 37378109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. General and abdominal obesity in relation to the prevalence of irritable bowel syndrome.
    Akhondi N; Memar Montazerin S; Soltani S; Saneei P; Hassanzadeh Keshteli A; Esmaillzadeh A; Adibi P
    Neurogastroenterol Motil; 2019 Apr; 31(4):e13549. PubMed ID: 30657237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced Risk of Alcohol-Induced Pancreatitis With Cannabis Use.
    Adejumo AC; Akanbi O; Adejumo KL; Bukong TN
    Alcohol Clin Exp Res; 2019 Feb; 43(2):277-286. PubMed ID: 30570765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Cannabis Use on Inpatient Inflammatory Bowel Disease Outcomes in 2 States Legalizing Recreational Cannabis.
    Pusateri A; Anaizi A; Nemer L; Hinton A; Lara L; Afzali A
    Crohns Colitis 360; 2022 Apr; 4(2):otac015. PubMed ID: 36777043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tenapanor for constipation-predominant irritable bowel syndrome.
    Siddiqui S; Cash BD
    Drugs Today (Barc); 2020 Mar; 56(3):203-210. PubMed ID: 32282867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irritable Bowel Syndrome in a Population of a Developing Country: Prevalence and Association.
    Latif A; Aziz Memon F; Asad M
    Cureus; 2020 May; 12(5):e8112. PubMed ID: 32542165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of irritable bowel syndrome and venous thromboembolism.
    Zöller B; Ohlsson H; Waehrens R; Sundquist J; Sundquist K
    Scand J Gastroenterol; 2018; 53(7):784-789. PubMed ID: 29688100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.